This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/scotland/6755015.stm

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Therapy 'combats ovarian cancer' Therapy 'combats ovarian cancer'
(1 day later)
A hormone therapy treatment used to tackle breast tumours has also proven successful in combating ovarian cancer, according to research. A hormone therapy treatment used to tackle breast tumours has also proved successful in combating ovarian cancer, according to research.
An Edinburgh University study found an anti-oestrogen drug could help prolong patients' lives by up to three years.An Edinburgh University study found an anti-oestrogen drug could help prolong patients' lives by up to three years.
It also delayed the need for some patients to undergo chemotherapy.It also delayed the need for some patients to undergo chemotherapy.
The professor who led the research programme described its findings as an "important landmark" in the research and treatment of ovarian cancer.The professor who led the research programme described its findings as an "important landmark" in the research and treatment of ovarian cancer.
Professor John F Smyth said: "Despite intense scientific research over the past 20 years, there have been few new leads in our understanding of how this disease operates.Professor John F Smyth said: "Despite intense scientific research over the past 20 years, there have been few new leads in our understanding of how this disease operates.
"But this study suggests that the addition of hormone therapy to our treatment strategy could extend and improve the lives of women with cancer.""But this study suggests that the addition of hormone therapy to our treatment strategy could extend and improve the lives of women with cancer."
Hormone therapyHormone therapy
Ovarian cancer affects one in 48 women, with almost 7,000 new cases being diagnosed in the UK every year.Ovarian cancer affects one in 48 women, with almost 7,000 new cases being diagnosed in the UK every year.
The current treatment involves surgery and chemotherapy, but most ovarian cancers return within two years.The current treatment involves surgery and chemotherapy, but most ovarian cancers return within two years.
The results of the Edinburgh research, funded by Cancer Research UK, were published in Clinical Cancer Research.The results of the Edinburgh research, funded by Cancer Research UK, were published in Clinical Cancer Research.
The treatment, known as Letrozole hormone therapy, has already been successful in tackling breast tumours.The treatment, known as Letrozole hormone therapy, has already been successful in tackling breast tumours.
Track progressTrack progress
It turns off the supply of the hormone oestrogen, a substance which is essential for the growth of some cancers.It turns off the supply of the hormone oestrogen, a substance which is essential for the growth of some cancers.
The study involved 44 women who were sensitive to oestrogen and whose cancer had relapsed after surgery and chemotherapy.The study involved 44 women who were sensitive to oestrogen and whose cancer had relapsed after surgery and chemotherapy.
Scientists were able to track the progress of the tumours during treatment by looking at levels of a molecule in the blood which is secreted by ovarian cancer.Scientists were able to track the progress of the tumours during treatment by looking at levels of a molecule in the blood which is secreted by ovarian cancer.
A quarter of the women showed no tumour growth after six months of anti-oestrogen therapy, while 33% of the group most sensitive to oestrogen showed a positive response which allowed chemotherapy to be delayed.A quarter of the women showed no tumour growth after six months of anti-oestrogen therapy, while 33% of the group most sensitive to oestrogen showed a positive response which allowed chemotherapy to be delayed.